Visceral fat accumulation, a key feature of the metabolic syndrome, is associated with the development of diabetes mellitus, a three-fold increased risk of developing coronary heart disease [1], a two to three times increase in cardiovascular mortality [2] and worse clinical outcome following an acute myocardial infarction [3–5] or a primary percutaneous coronary intervention [6]. Although formerly regarded as purely an energy storage site, the emerging studies suggest that adipose tissue is an active endocrine organ producing ‘adipocytokines’, hormones that influence a diverse array of processes including appetite and energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid metabolism and haemostasis, all factors that can impact cardiovascular disease [7]. In this regard, the adipocytokines, adiponectin [8], leptin [9] and apelin [10], have been linked to cardioprotection in recent experimental studies.

The recently discovered adipocytokine, visfatin, has been demonstrated to mimic the glucose-lowering effect of insulin and improve insulin sensitivity [11]. Furthermore, by binding to the insulin receptor, visfatin has been demonstrated to activate intracellular kinase signalling cascades, such as the PI3K-Akt and mitogen-activated protein kinase (MAPK) pathways [11], through which it may exert an antiapoptotic effect [12]. Experimental studies have indicated that the activation of pro-survival protein kinases such as PI3K-Akt and MEK1/2-MAPK, at the time of myocardial reperfusion [13, 14], confers powerful cardioprotection, an effect attributable, in part, to the inhibition of the mitochondrial permeability transition pore (mPTP) [15].

The novel adipocytokine visfatin exerts direct cardioprotective effects

Shiang Y. Lim, Sean M. Davidson, Ajeev J. Paramanathan, Christopher C. T. Smith, Derek M. Yellon*, Derek J. Hausenloy

Abstract

Visfatin is an adipocytokine capable of mimicking the glucose-lowering effects of insulin and activating the pro-survival kinases phosphatidylinositol-3-OH kinase (PI3K)-protein kinase B (Akt) and mitogen-activated protein kinase 1 and 2 (MEK1/2)-extracellular signal-regulated kinase 1 and 2 (Erk 1/2). Experimental studies have demonstrated that the activation of these kinases confers cardioprotection through the inhibition of the mitochondrial permeability transition pore (mPTP). Whether visfatin is capable of exerting direct cardioprotective effects through these mechanisms is unknown and is the subject of the current study. Anaesthetized C57BL/6 male mice were subjected to in situ 30 min. of regional myocardial ischaemia and 120 min. of reperfusion. The administration of an intravenous bolus of visfatin (5 x 10^{-6} μmol) at the time of myocardial reperfusion reduced the myocardial infarct size from 46.1 ± 4.1% in control hearts to 27.3 ± 4.0% (n ≥ 6/group, P < 0.05), an effect that was blocked by the PI3K inhibitor, wortmannin, and the MEK1/2 inhibitor, U0126 (48.8 ± 5.5% and 45.9 ± 8.4%, respectively, versus 27.3 ± 4.0% with visfatin; n ≥ 6/group, P < 0.05). In murine ventricular cardiomyocytes subjected to 30 min. of hypoxia followed by 30 min. of reoxygenation, visfatin (100 ng/ml), administered at the time of reoxygenation, reduced the cell death from 65.2 ± 4.6% in control to 49.2 ± 3.7% (n > 200 cells/group, P < 0.05), an effect that was abrogated by wortmannin and U0126 (68.1 ± 5.2% and 59.7 ± 6.2%, respectively; n > 200 cells/group, P > 0.05). Finally, the treatment of murine ventricular cardiomyocytes with visfatin (100 ng/ml) delayed the opening of the mPTP induced by oxidative stress from 81.2 ± 4 sec. in control to 120 ± 7 sec. (n > 20 cells/group, P < 0.05) in a PI3K- and MEK1/2-dependent manner. We report that the adipocytokine, visfatin, is capable of reducing myocardial injury when administered at the time of myocardial reperfusion in both the in situ murine heart and the isolated murine cardiomyocytes. The mechanism appears to involve the PI3K and MEK1/2 pathways and the mPTP.

Keywords: visfatin • ischaemia • reperfusion • cardioprotection

Introduction

Visceral fat accumulation, a key feature of the metabolic syndrome, is associated with the development of diabetes mellitus, a three-fold increased risk of developing coronary heart disease [1], a two to three times increase in cardiovascular mortality [2] and worse clinical outcome following an acute myocardial infarction [3–5] or a primary percutaneous coronary intervention [6]. Although formerly regarded as purely an energy storage site, the emerging studies suggest that adipose tissue is an active endocrine organ producing ‘adipocytokines’, hormones that influence a diverse array of processes including appetite and energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid metabolism and haemostasis, all factors that can impact cardiovascular disease [7]. In this regard, the adipocytokines, adiponectin [8], leptin [9] and apelin [10], have been linked to cardioprotection in recent experimental studies.

The recently discovered adipocytokine, visfatin, has been demonstrated to mimic the glucose-lowering effect of insulin and improve insulin sensitivity [11]. Furthermore, by binding to the insulin receptor, visfatin has been demonstrated to activate intracellular kinase signalling cascades, such as the PI3K-Akt and mitogen-activated protein kinase (MAPK) pathways [11], through which it may exert an antiapoptotic effect [12]. Experimental studies have indicated that the activation of pro-survival protein kinases such as PI3K-Akt and MEK1/2-MAPK, at the time of myocardial reperfusion [13, 14], confers powerful cardioprotection, an effect attributable, in part, to the inhibition of the mitochondrial permeability transition pore (mPTP) [15].
a non-specific mitochondrial channel whose opening in the first few minutes of myocardial reperfusion is a critical determinant of the cardiomyocyte death [16, 17]. In addition, several studies have reported that the visfatin gene is induced in response to hypoxia, an effect mediated by hypoxia-inducible factor [18, 19], raising the possibility that visfatin is up-regulated in response to myocardial ischaemia. In the current study, we have suggested that visfatin elicits cardioprotection through the activation of PI3K-Akt and MEK1/2-Erk1/2 and the subsequent inhibition of mPTP opening.

Methods

Animals and materials

Experiments were carried out in accordance with the United Kingdom Home Office Guide on the Operation of Animals (Scientific Procedures) Act of 1986. C57BL/6 male mice were obtained from Charles River UK Limited (Margate, UK). Wortmannin (Tocris Bioscience, Bristol, UK), U0126 (Tocris Bioscience) and cyclosporin A (CsA) (Calbiochem, San Diego, CA, USA) were dissolved in dimethyl sulfoxide (DMSO) (0.02%). Visfatin (Alexis Biochemical, Lausen, Switzerland) was dissolved in normal saline.

In vivo murine model of acute myocardial infarction

C57BL/6 male mice (8–12 weeks of age and weighing 25–30 g) were anaesthetized by intraperitoneal injection with a combination of ketamine, xylazine and atropine (0.01 ml/g; the final concentrations of ketamine, xylazine and atropine were 10 mg/ml, 2 mg/ml and 0.06 mg/ml, respectively) and their body temperature was maintained at 37°C. The external jugular vein and carotid artery were isolated and cannulated for drug administration and mean arterial blood pressure (MABP) measurement, respectively. A tracheotomy was performed for artificial respiration at administration and mean arterial blood pressure (MABP) measurement, jugular vein and carotid artery were isolated and cannulated for drug administration. At the end of the reperfusion, the heart was rapidly excised, cannulated and used for perfusion with perfusion buffer containing 0.9 mg/ml collagenase type II (Worthington Biochemical Corporation, Lakewood, NJ, USA) 0.125 mg/ml hyaluronidase and 12.5 µmol/L CaCl2 for 10 min. The hearts were injected with heparin sodium (250 IU) and anaesthetized with ketamine/xylazine/atropine. The hearts were randomly assigned to one of the following six treatment groups (Fig. 1). The hearts were subjected to 30 min. of ischaemia, followed by 120 min. of reperfusion at the end of which the infarct size was determined by tetrazolium staining.

1) Vehicle control (n = 13): either 0.02% DMSO or normal saline (0.1 ml) was administered immediately prior to the onset of myocardial reperfusion.
2) Visfatin (n = 8): an intravenous bolus of Visfatin (5 × 10^{-6} µmol, 0.1 ml) dissolved in normal saline was administered immediately prior to the onset of myocardial reperfusion.
3) Visfatin + wortmannin (n = 6): visfatin was administered in the presence of wortmannin (15 µg/kg) dissolved in DMSO (0.02%) immediately prior to the onset of reperfusion.
4) Wortmannin or U0126 (n = 6): visfatin was administered in the presence of U0126 (0.2 mg/kg) dissolved in DMSO (0.02%) immediately prior to the onset of reperfusion.
5, 6) Wortmannin or U0126 (n = 4): wortmannin or U0126 was administered alone immediately prior to the onset of reperfusion.

Experimental protocol for murine myocardial infarction studies

The mice were injected with heparin sodium (250 IU) and anaesthetized with ketamine/xylazine/atropine. The hearts were rapidly excised, cannulated and perfused with (in mmol/L) 113.0 NaCl, 4.7 KCl, 0.6 K2HPO4, 0.6 Na2HPO4, 1.2 MgSO4·7H2O, 12.0 NaHCO3, 1.0 KClO3, 30.0 tauroine, 10.0 HEPES, and 5.5 glucose, saturated with 95% O2–5% CO2 at 37°C. The hearts were perfused at 3 ml/min. with perfusion buffer for 4 min., then with perfusion buffer containing 0.9 mg/ml collagenase type II (Worthington Biochemical Corporation, Lakewood, NJ, USA) 0.125 mg/ml hyaluronidase and 12.5 µmol/L CaCl2 for 10 min. The hearts were then cut into several pieces and shaken at 37°C with oxygenation for 10 min. The supernatant was collected and 5% foetal calf serum was added. After centrifugation at 600 rpm for 3 min., the cell pellet was suspended in 10 ml of perfusion buffer containing 12.5 µmol/L CaCl2 and the calcium concentration was gradually restored to 1 mmol/L over 20 min. The myocytes were then re-centrifuged, then seeded onto sterilized laminin-coated coverslips in minimum essential medium (MEM) containing 10 units/ml penicillin, 10 µg/ml streptomycin and 5% foetal calf serum for incubation before use on the same day of isolation.

Experimental protocol for murine ventricular cardiomyocyte isolation

All cells were subjected to 30 min. of hypoxia, then 30 min. of reoxygenation to simulate ischaemia-reperfusion injury. Hypoxia was induced in a custom-made airtight hypoxic chamber using a buffer simulating the conditions of ischaemia (in mmol/L: 1.0 KH2PO4, 10.0 NaHCO3, 1.2 MgCl2·6H2O, 25.0 Na[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] (HEPES), 74.0 NaCl, 16.0 KCl, 1.2 CaCl2 and 20.0 Na lactate, pH 6.7), bubbled with 95% nitrogen/5% CO2. Reoxygenation was achieved by replacing the buffer with a solution containing (in mmol/L) 1.0 KH2PO4, 10.0 NaHCO3, 1.2 MgCl2·6H2O, 25.0 NaHEPES, 98.0 NaCl, 3.0 KCl, 1.2 CaCl2,
10.0 D-glucose, 2.0 Na pyruvate, pH 7.4, bubbled with 95% O₂/5% CO₂. The cells were randomized to the following six treatment groups (n > 200 cells per group from three to six different animals).

1) Vehicle control: cells were reoxygenated in normal buffer or buffer containing 0.02% DMSO.
2) Visfatin: cells were reoxygenated in buffer containing visfatin (100 ng/ml).
3) Visfatin + wortmannin: cells were reoxygenated in buffer containing visfatin and wortmannin (100 nmol/L).
4) Vistatin + U0126: cells were reoxygenated in buffer containing visfatin and U0126 (10 μmol/L).
5,6) Wortmannin or U0126: Cells were reoxygenated in buffer containing either wortmannin or U0126.

At the end of the reoxygenation, 5 μL of propidium iodide (PI, 1 μg/ml) was added to the cells for 5 min. followed by 1 ml of 10% neutral buffer formalin. The percentage of dead cells (as indicated by red fluorescence, PI-positive) in duplicate wells was calculated by fluorescence microscopy and was expressed as a percentage of the total number of cardiomyocytes (PI-positive and PI-negative).

Assay of mPTP opening

The sensitivity of the mPTP to opening was assayed using a well-characterized and reproducible cellular model [9, 15]. Live isolated myocytes were incubated with the fluorescent dye tetra-methyl rhodamine methyl ester (TMRM, 3 μmol/L) for 15 min. in microscopy buffer (i.e. perfusion buffer containing 1.2 mmol/L CaCl₂), then washed and imaged using confocal microscopy. TMRM, a lipophilic cation, accumulates selectively into the mitochondria according to the mitochondrial membrane potential. Continual confocal laser scanning generates reactive oxygen species (ROS) from the TMRM within the mitochondria that, after several minutes, provoke mPTP opening, as indicated by the mitochondrial depolarization. After loading with TMRM, and before confocal laser illumination, the cardiomyocytes were randomly assigned to the following treatment groups (n > 20 cells per group from three to five different mice):

1) Vehicle control: cardiomyocytes were bathed in buffer containing either 0.02% DMSO or normal saline.
2) Visfatin: cardiomyocytes were treated with visfatin (100 ng/ml) for 5 min.
3) Visfatin + wortmannin: cardiomyocytes were treated with visfatin and wortmannin (100 nmol/L) for 5 min.
4) Vistatin + U0126: cardiomyocytes were treated with visfatin and U0126 (10 μmol/L) for 5 min.
5,6) Wortmannin or U0126: cardiomyocytes were treated with either wortmannin or U0126 for 5 min.
7) CsA: cardiomyocytes were treated with CsA (0.4 μmol/L) for 5 min.

Statistical analysis

All values are expressed as mean ± standard error of mean (S.E.M.). Infarct size to AAR, cell viability data and the time taken to induce mPTP opening were analysed by one-way ANOVA followed by Dunnett’s multiple comparison post-hoc test. The differences were considered significant when P < 0.05.

Results

In general, except for the increase in MABP in the wortmannin-treated hearts, the treatment with visfatin and/or the kinase inhibitors had no significant effects on the haemodynamic parameters of MABP and heart rate (Table 1).
Visfatin reduces the myocardial infarct size in vivo when administered at the time of reperfusion through PI3K and MEK1/2

The AAR of myocardial infarction was comparable among the treatment groups (42.1 ± 2.0% in control versus 53.2 ± 8.0% visfatin, 53.6 ± 8.0% visfatin + wortmannin, 47.2 ± 5.0% visfatin + U0126, 48.2 ± 3.0% wortmannin, 49.2 ± 9.0% U0126; P > 0.05). Visfatin, given at the time of myocardial reperfusion, reduced the infarct size from 46.1 ± 4.1% in control to 27.3 ± 4.0% (P < 0.05; Fig. 2). Wortmannin and U0126 both abolished the decrease in the infarct size observed in the visfatin-treated hearts (46.1 ± 4.1% in control versus 48.8 ± 5.5% with visfatin + wortmannin and 45.9 ± 8.4% with visfatin and U0126; Fig. 2). The administration of wortmannin or U0126 alone had no effect on the infarct size (46.1 ± 4.1% in control versus 51.2 ± 5.1% with wortmannin and 40.5 ± 8.9% with U0126; P > 0.05; Fig. 2). The infarct size is plotted against the AAR in Fig. 3.

Visfatin reduces the cardiomyocyte death when administered at the time of reoxygenation through PI3K and MEK1/2

In murine ventricular cardiomyocytes subjected to an episode of sustained hypoxia, the presence of visfatin at the time of reoxygenation reduced the cell death from 65.2 ± 4.6% in control to 49.2 ± 3.7% with visfatin (P < 0.05; Fig. 4). The cardioprotective effect of visfatin was abrogated in the presence of wortmannin and U0126 (65.2 ± 4.6% in control versus 68.1 ± 5.2% with visfatin + wortmannin and 59.7 ± 6.2% with visfatin + U0126; P > 0.05; Fig. 4). The kinase inhibitors alone did not influence the cardiomyocyte viability (65.2 ± 4.6% in control versus...
Visfatin delays the mPTP opening in a PI3K- and MEK1/2-dependent manner

The treatment of cardiomyocytes with visfatin delayed the time taken to induce mPTP opening from 81.2 ±4.0 sec. in control to 120.0 ±6.5 sec. with visfatin (P < 0.01; Fig. 5). The inhibitory effect of visfatin on the mPTP opening was abrogated in the presence of the PI3K and MEK1/2 inhibitors, wortmannin and U0126 (83.4 ±3.4 sec. with visfatin + wortmannin and 80.9 ±8.1 sec. with visfatin + U0126; P > 0.05; Fig. 5). The kinase inhibitors alone did not influence the cardiomyocyte mPTP opening (81.2 ±4.0 sec. in control versus 75.7 ±6.5 sec. with wortmannin and 77.0 ±4.8 sec. with U0126; P > 0.05; Fig. 5).

Discussion

The pivotal findings of the current study are as follows: (1) we demonstrate for the first time that the administration of the novel adipocytokine, visfatin, specifically at the time of myocardial reperfusion, dramatically reduces the myocardial infarct size using an in vivo murine infarction model; (2) the cardioprotective effect induced by visfatin is demonstrated to be a direct cellular effect, as demonstrated by the improved cardiomyocyte viability observed using isolated cardiomyocytes treated with visfatin at the time of reoxygenation; (3) visfatin treatment delays the opening of the mPTP in isolated cardiomyocytes subjected to oxidative stress and (4) importantly, the cardioprotective effect is dependent on the activation of the pro-survival kinases, PI3K and MEK1/2.

Visfatin has only recently been discovered as an adipocytokine, and as such, its pathophysiological role, in common with some of the other newer adipocytokines, remains to be determined. Fukuhara et al. [11] first identified visfatin in 2005, as an adipocytokine that appeared to lower the serum glucose by mimicking the actions of insulin, thereby raising the exciting possibility of a novel antidiabetic agent [11]. In the same study, the authors demonstrated that visfatin phosphorylated the insulin receptor, insulin receptor substrate-1 (IRS-1) and -2 (IRS-2), PI3K, Akt and MAPK [11]. However, whether visfatin actually mediates its effects by binding to the insulin receptor has been recently debated [21].

Given that visfatin has the ability to activate Akt and MAPK, and the prior knowledge that these kinases belong to the reperfusion injury salvage kinase (RISK) pathway [13, 14], a group of protein kinases that on activation at the time of myocardial reperfusion confer powerful cardioprotection, we were keen to determine whether visfatin was able to confer protection against acute myocardial ischaemia-reperfusion injury. In the present study, although we demonstrated that specific pharmacological blockers of the RISK pathway abolished the protection elicited by visfatin, a limitation of our study is that we did not determine whether
Fig. 4 Cell viability following 30 min. of hypoxia and 30 min. of reoxygenation in murine ventricular cardiomyocytes treated with visfatin (100 ng/ml) in the presence or absence of the PI3K and MEK1/2 inhibitors wortmannin (Wort, 100 nmol/L) and U0126 (10 μmol/L), respectively. Visfatin reduces the percentage cardiomyocyte death elicited by hypoxia-reoxygenation injury, and this cardioprotective effect is abolished in the presence of the kinase inhibitors. n > 200 cells per group. *P < 0.05.
Visfatin treatment resulted in the phosphorylation of kinases of Akt and Erk1/2. Given that the cardioprotection mediated through the RISK pathway has been linked to the inhibition of the mPTP [15], a non-specific high-conductance channel of the inner mitochondrial membrane that is believed to mediate lethal reperfusion injury by opening in the first few minutes of myocardial reperfusion [16], it was important in the current study to link the protective effect of visfatin with the inhibition of mPTP opening. It must be appreciated that although the model we used to detect mPTP opening in the current study is a well-established and reproducible model [9, 15], it was limited by the fact that it only reproduced the oxidative stress component of ischaemia-reperfusion injury to provoke mPTP opening.

As described above, the pathophysiological role of visfatin is currently unclear. The clinical studies in which plasma levels of visfatin were measured in different patient groups showed no clear correlations. Indeed, measurements of plasma visfatin levels in human beings have yielded conflicting results, with raised levels being reported in obese children [22], diabetic patients [23, 24], patients after weight loss mediated by gastroplastic surgery [25] and patients being treated with thiazolidinedione and rosiglitazone [26], whilst other studies have reported reduced levels with gestational diabetes [27], exercise in patients with type 1 diabetes [28], massive weight loss [29] and obesity [30].

Interestingly, visfatin was formerly identified as a pre-B cell colony-enhancing factor (PBEF) [31], a growth factor for early B cells, which has been linked to a diverse variety of cellular processes, with studies demonstrating PBEF to (a) act as a biomarker of acute lung injury [32, 33], (b) be up-regulated in infected foetal membranes [34], (c) inhibit neutrophil apoptosis in experimental inflammation and clinical sepsis [12] and (d) participate in the maturation of vascular smooth muscle cells through a nicotinamide adenine dinucleotide (NAD⁺)-dependent mechanism [35]. Intriguingly, PBEF/visfatin has also been identified as the enzyme nicotinamide phosphoribosyl transferase (Nampt), the rate-limiting enzyme in NAD biosynthesis that mediates the conversion of nicotinamide to nicotinamide mononucleotide [36]. Given the pivotal role of Nampt in NAD biosynthesis, pharmacological inhibitors of Nampt such as FK866 are currently being investigated as potential novel anticancer agents [37, 38]. Clearly, further studies are required to elucidate the pathophysiological role of visfatin in relation to these previous identities of PBEF and Nampt. For example, the possibility that the cardioprotective effect elicited by visfatin could be due to the potentiation of Nampt, which would be expected to up-regulate NAD biosynthesis, thereby enhancing energy metabolism and redox biochemistry, factors that underpin the tolerance of myocardial tissue to ischaemic injury, requires investigation.

Whether endogenous visfatin contributes to cardioprotection in the clinical setting is unclear; but in this regard, it is interesting that the experimental studies have reported that the visfatin gene is induced in response to hypoxia, an effect mediated by hypoxia-inducible factor [18, 19], raising the possibility that visfatin may be up-regulated in response to myocardial ischaemia. Thus, further studies are required to ascertain the plasma levels of visfatin in patients presenting with an acute myocardial infarction. The recent investigations have linked visfatin with MAPK-mediated angiogenesis [39] as well as a potential pro-inflammatory mediator in unstable atherosclerotic plaques, suggesting that endogenous visfatin may have a detrimental effect in coronary artery disease [40]. In the current study, we found that the acute administration of exogenous visfatin can protect against acute myocardial ischaemia-reperfusion injury in a non-atherosclerotic animal model of myocardial infarction and in isolated cardiomyocytes. Further studies will be required to determine whether exogenous visfatin elicits the same cardioprotective benefits in the atherosclerotic models of myocardial infarction.
In summary, this study has demonstrated, for the first time, that the novel adipocytokine, visfatin, has the ability to reduce the myocardial infarct size when administered at the time of myocardial reperfusion. This powerful cardioprotective effect appears to be a direct cellular effect that is mediated through the activation of PI3K and MEK1/2 and the inhibition of mPTP opening.

Acknowledgements

We thank the British Heart Foundation for continuing support and the Wellcome Trust for funding of the confocal microscope. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme.

References

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24: 683–9.

2. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110: 1245–50.

3. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRAACL) trial. Diabetes Care. 2005; 28: 2508–13.

4. Zeller M, Steg PG, Ravisly J, Laurent Y, Janin-Manificat L, L’Huillier I, Beer JC, Oudot A, Ricoulot G, Makki H, Farnier M, Rochette L, Verges B, Cottil Y. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005; 165: 1192–8.

5. Clavijo LC, Pinto TL, Kuchukaliak PK, Torguson R, Chu WW, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med. 2006; 7: 7–11.

6. Celik T, Turhan H, Kursaktioglu H, Ilyisoy A, Yuksel UC, Ozmen N, Isik E. Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Coron Artery Dis. 2006; 17: 339–43.

7. Matsuza Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006; 3: 35–42.

8. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK- and COX-2 dependent mechanisms. Nat Med. 2005; 11: 1096–103.

9. Smith CC, Mizan MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol. 2006; 149: 5–13.

10. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 2007; 102: 518–28.

11. Fukuura A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuoka Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamaneoka S, Hiramatu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426–30.

12. Jia SH, Li Y, Farooq J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004; 113: 1318–27.

13. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK) pathway. Cardiovasc Res. 2004; 63: 448–60.

14. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007; 12: 217–34.

15. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardio-protection. Int J Biochem Cell Biol. 2006; 38: 414–9.

16. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 2003; 35: 339–41.

17. Griffiths EJ, Halsestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995; 307: 93–8.

18. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, Yun I, Yoo MA, Bae MK. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 2006; 580: 4105–13.

19. Segawa K, Fukuura A, Hosogai N, Morita K, Okuno Y, Tanaka M, Nakagawa Y, Kihara S, Funahashi T, Komuro R, Matsuda M, Shimomura I. Visfatin in adipocytes is upregulated by hypoxia through HIF-1alpha-dependent mechanism. Biochem Biophys Res Commun. 2006; 349: 875–82.

20. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res. 2007; 75: 530–5.

21. Fukuura A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuoka Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamaneoka S, Hiramatu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426–30.

22. Haider DG, Holzer G, Schaller G, Weghuber D, Wiedhahn K, Wagner O, Kapitos S, Wolzt M. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006; 43: 548–9.

23. Chen HP, Cheng FM, Chang DM, Tsai JC, Huang HF, Shih SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing
factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91: 295–9.

24. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurts A, Bingol S. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007; 76: 24–9.

25. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity. 2006; 14: 1886–9.

26. Haider DG, Mittermayer F, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006; 291: E885–90.

27. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, Tsai EM. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Invest. 2006; 13: 364–7.

28. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Muller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab. 2006; 91: 4702–4.

29. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, Tondolo V, Calvani M, Ricart W, Castagneto M, Mingrone G. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. 2007; 92: 483–90.

30. Pagano C, Pilon C, Olivier M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federispil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91: 3165–70.

31. Samal B, Sun YH, Stearns G, Xie CS, Suggs S, Mcniece I. Cloning and characterization of the cDNA-encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14: 1431–7.

32. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res. 2005; 70: 142–51.

33. Garcia JG, Moreno VL. Genomic insights into acute inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2006; 291: L1113–7.

34. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol. 2001; 26: 107–17.

35. van der Veer E, Hong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005; 97: 25–34.

36. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002; 32: 3225–34.

37. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003; 63: 7436–42.

38. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006; 13: 582–8.

39. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, Jang HO, Yun I, Yoon KH, Kim YJ, Yoo MA, Kim KW, Bae MK. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007; 357: 150–6.

40. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damas JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Froland SS, Krohg-Sorensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115: 972–80.
Author/s: 
Lim, SY; Davidson, SM; Paramanathan, AJ; Smith, CCT; Yellon, DM; Hausenloy, DJ

Title: 
The novel adipocytokine visfatin exerts direct cardioprotective effects.

Date: 
2008-08

Citation: 
Lim, S. Y., Davidson, S. M., Paramanathan, A. J., Smith, C. C. T., Yellon, D. M. & Hausenloy, D. J. (2008). The novel adipocytokine visfatin exerts direct cardioprotective effects.. J Cell Mol Med, 12 (4), pp.1395-1403. https://doi.org/10.1111/j.1582-4934.2008.00332.x.

Persistent Link: 
http://hdl.handle.net/11343/259203

File Description: 
Published version

License: 
CC BY